Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Linehan

Showing results (151-160 of 252) with videos related to

Pageof 26
Sort By:
Oncogene|June 1, 1994
Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell linesY Sekido, S Bader, F Latif, et al.
Cancer|January 1, 1992
A pilot trial of chemohormonal therapy for metastatic prostate carcinomaN A Dawson, G Wilding, R B Weiss, et al.
Journal of Computer Assisted Tomography|September 19, 1997
Imaging features of hereditary papillary renal cancersP L Choyke, M M Walther, G M Glenn, et al.
The Journal of Surgical Research|August 1, 1992
Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in cultureT P Wade, A Kasid, C A Stein, et al.
The Journal of Urology|August 1, 1993
Regression of metastatic renal cell carcinoma after cytoreductive nephrectomyS G Marcus, P L Choyke, R Reiter, et al.
JAMA|March 4, 1992
Screening for von Hippel-Lindau disease by DNA polymorphism analysisG M Glenn, W M Linehan, S Hosoe, et al.
The American Journal of Pathology|August 6, 1999
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotypeI A Lubensky, L Schmidt, Z Zhuang, et al.
The Journal of Urology|March 21, 2001
Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epitheliumD K Ornstein, M Cinquanta, S Weiler, et al.
The Canadian Journal of Urology|September 21, 2001
Retroperitoneoscopic-guided radiofrequency ablation of renal tumorsS E Pautler, C P Pavlovich, I Mikityansky, et al.
Journal of the National Cancer Institute|February 2, 1994
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancerO Sartor, M Cooper, M Weinberger, et al.
Pageof 26

Showing results (151-160 of 252) with videos related to

Sort By:
Pageof 26
Oncogene|June 1, 1994
Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell linesY Sekido, S Bader, F Latif, et al.
Cancer|January 1, 1992
A pilot trial of chemohormonal therapy for metastatic prostate carcinomaN A Dawson, G Wilding, R B Weiss, et al.
Journal of Computer Assisted Tomography|September 19, 1997
Imaging features of hereditary papillary renal cancersP L Choyke, M M Walther, G M Glenn, et al.
The Journal of Surgical Research|August 1, 1992
Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in cultureT P Wade, A Kasid, C A Stein, et al.
The Journal of Urology|August 1, 1993
Regression of metastatic renal cell carcinoma after cytoreductive nephrectomyS G Marcus, P L Choyke, R Reiter, et al.
JAMA|March 4, 1992
Screening for von Hippel-Lindau disease by DNA polymorphism analysisG M Glenn, W M Linehan, S Hosoe, et al.
The American Journal of Pathology|August 6, 1999
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotypeI A Lubensky, L Schmidt, Z Zhuang, et al.
The Journal of Urology|March 21, 2001
Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epitheliumD K Ornstein, M Cinquanta, S Weiler, et al.
The Canadian Journal of Urology|September 21, 2001
Retroperitoneoscopic-guided radiofrequency ablation of renal tumorsS E Pautler, C P Pavlovich, I Mikityansky, et al.
Journal of the National Cancer Institute|February 2, 1994
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancerO Sartor, M Cooper, M Weinberger, et al.
Pageof 26